We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
For the first time in the UK, obese patients and people who are overweight with weight-related health problems could now have access to Mounjaro, currently used for Type 2 diabetes, to help manage their weight and support we…
Patients with a certain type of advanced or spreading non-small cell lung cancer (NSCLC) could access a new cancer therapy to help treat their condition.
Patients with severe alopecia areata (patchy hair loss) could access a new medicine to help treat their condition.
Patients with recurring lymphoma, or who have not responded to prior treatments, could access a new bispecific antibody therapy to help treat their condition.
The vaccine was approved after it was found to meet the MHRA’s standards of safety, quality and effectiveness.
The vaccine was approved after it was found to meet the UK regulator's standards of safety, quality and effectiveness
The new COVID-19 vaccine from SK Chemicals, has been authorised after meeting the MHRA’s required safety, quality and effectiveness standards.
The government, NHS England and the pharmaceutical industry will begin negotiating the successor to the voluntary scheme for branded medicines, pricing and access (VPAS).
First published during the 2022 to 2024 Sunak Conservative government
The Comirnaty COVID vaccine has met the MHRA’s required safety, quality and effectiveness standards to be authorised for use in this age group
It is the first treatment approved by the UK regulator that has been made possible through the Access Consortium ‘New Active Substance Work Sharing Initiative’.
Use of the Moderna COVID-19 vaccine or ‘Spikevax’ has been approved for 6 to 11s after meeting the required safety, quality and effectiveness standards
The government announces its intention to introduce a licensing regime for non-surgical cosmetic procedures such as Botox and fillers.
First published during the 2019 to 2022 Johnson Conservative government
A reflection by Dr June Raine, Chief Executive of the Medicines and Healthcare products Regulatory Agency
This monoclonal antibody – the second to be authorised by the Medicines and Healthcare products Regulatory Agency – is for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
The antiviral was found to be safe and effective following a stringent review of the available evidence.
AWTTC joins the Innovative Licensing and Access Pathway as a permanent partner
Regulatory updates by the MHRA today on the COVID-19 booster vaccine programme for winter 2021 to 2022
The regulatory changes made by the MHRA today give further options for the deployment programme.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today given approval for the first monoclonal antibody treatment for the prevention and treatment of COVID-19 in the UK.
The UK regulator has confirmed the vaccine is safe and effective in this age group.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).